TW202415380A - 索托拉西布給藥方案 - Google Patents

索托拉西布給藥方案 Download PDF

Info

Publication number
TW202415380A
TW202415380A TW111148499A TW111148499A TW202415380A TW 202415380 A TW202415380 A TW 202415380A TW 111148499 A TW111148499 A TW 111148499A TW 111148499 A TW111148499 A TW 111148499A TW 202415380 A TW202415380 A TW 202415380A
Authority
TW
Taiwan
Prior art keywords
cancer
patient
dose
rosuvastatin
sotolacib
Prior art date
Application number
TW111148499A
Other languages
English (en)
Chinese (zh)
Inventor
卡多納潘禮
布萊特 Ｅ 霍克
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202415380A publication Critical patent/TW202415380A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111148499A 2022-09-30 2022-12-16 索托拉西布給藥方案 TW202415380A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263411789P 2022-09-30 2022-09-30
US63/411,789 2022-09-30

Publications (1)

Publication Number Publication Date
TW202415380A true TW202415380A (zh) 2024-04-16

Family

ID=85158814

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111148499A TW202415380A (zh) 2022-09-30 2022-12-16 索托拉西布給藥方案

Country Status (9)

Country Link
US (1) US20260083741A1 (https=)
EP (1) EP4593837A1 (https=)
JP (1) JP2025533334A (https=)
KR (1) KR20250079183A (https=)
AU (1) AU2022479909A1 (https=)
JO (1) JOP20250064A1 (https=)
MX (1) MX2025003741A (https=)
TW (1) TW202415380A (https=)
WO (1) WO2024072437A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013557A (es) * 2021-05-18 2023-11-29 Amgen Inc Pauta posologica de sotorasib.

Also Published As

Publication number Publication date
US20260083741A1 (en) 2026-03-26
EP4593837A1 (en) 2025-08-06
AU2022479909A1 (en) 2025-02-06
KR20250079183A (ko) 2025-06-04
WO2024072437A1 (en) 2024-04-04
MX2025003741A (es) 2025-05-02
JOP20250064A1 (ar) 2025-03-25
JP2025533334A (ja) 2025-10-06

Similar Documents

Publication Publication Date Title
US20220323446A1 (en) Sotorasib dosing regimen
US20250375452A1 (en) Sotorasib dosing regimen
WO2024006187A1 (en) Combination treatment for treating cancer carrying kras g12c mutations
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
TW202415380A (zh) 索托拉西布給藥方案
CA3269092A1 (en) Sotorasib dosing regimen
AU2023366820A1 (en) Methods of treating cancer with sotorasib
EA053101B1 (ru) Способы лечения рака с помощью соторасиба
CN116981462A (zh) 索托拉西布给药方案
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
HK40111140A (zh) 用於治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
HK40102675A (zh) 索托拉西布给药方案